
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
 Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
 Definitive Proxy Statement
 Definitive Additional Materials
 Soliciting Material Pursuant to §240.14a-12

ALKERMES PLC

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply)

- No fee required
 Fee paid previously with preliminary materials
 Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
-

On June 20, 2023, Alkermes plc (the “Company”) updated the website (<https://www.alkermesvalue.com/>) it launched in connection with the Company’s 2023 annual general meeting of shareholders. A copy of the updated page on the website can be found below:

Recent Relevant Alkermes News

Recent Relevant Alkermes News

6/20/23

[Independent Proxy Advisory Firm ISS Recommends Alkermes Shareholders Vote Against Sarissa Employees' Election to Alkermes Board](#)

6/13/23

[Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors](#)

6/8/23

[Alkermes Publishes Investor Presentation Detailing Company's Transformation and Value Creation](#)

6/6/23

[Alkermes Announces Final Award in Janssen Pharmaceutica Arbitration and Provides Updated Financial Expectations](#)

6/1/23

[Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc](#)

5/25/23

[Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value](#)

5/8/23

[Alkermes Files Preliminary Proxy Statement and Provides Update on Annual Director Nomination Process](#)

4/26/23

[Alkermes plc Reports First Quarter 2023 Financial Results](#)

4/25/23

[Alkermes Announces Second Interim Award in Janssen Pharmaceutica Arbitration](#)

4/18/23

[Alkermes Announces Submission of Confidential Draft Form 10 Registration Statement for Planned Separation of Oncology Business](#)

2/16/23

[Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2022 and Provides Financial Expectations for 2023](#)

11/2/22

[Alkermes plc Reports Third Quarter 2022 Financial Results](#)

11/2/22

11/2/22

Alkermes plc Announces Intent to Separate Oncology Business

7/27/22

Alkermes plc Reports Second Quarter 2022 Financial Results

7/7/22

Alkermes Announces Results of Annual General Meeting of Shareholders

5/26/22

Alkermes Announces Continued Board Refreshment, Including the Appointment of Christopher I. Wright, M.D., Ph.D. to its Board of Directors

4/27/22

Alkermes plc Reports First Quarter 2022 Financial Results

4/19/22

Alkermes Commences Arbitration Related to License Agreements with Janssen Pharmaceutica

2/16/22

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2021 and Provides Financial Expectations for 2022

11/19/21

Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors

5/20/21

Alkermes Announces the Appointment of Emily Peterson Alva to its Board of Directors

4/30/21

Alkermes Announces Agreement with Sarissa Capital

3/25/21

Alkermes Investor Day to Focus on Scientific Progress and Value Creation Strategy

1/6/21

Alkermes Announces Updates to Executive Leadership Team

12/10/20

Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment

[Click here to access all Alkermes press releases](#)



[Contact Us](#)

[Terms of Use](#)

[Privacy Policy](#)

[Sitemap](#)



© 2023 Alkermes. All rights reserved.